While Alx Oncology Holdings Inc has underperformed by -2.28%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALXO rose by 128.95%, with highs and lows ranging from $17.42 to $3.94, whereas the simple moving average jumped by 17.46% in the last 200 days.
On March 08, 2024, Stifel Downgraded Alx Oncology Holdings Inc (NASDAQ: ALXO) to Hold. A report published by Jefferies on December 08, 2023, Upgraded its rating to ‘Buy’ for ALXO. Jefferies also Downgraded ALXO shares as ‘Hold’, setting a target price of $25 on the company’s shares in a report dated December 22, 2021. Stifel Initiated an Buy rating on September 30, 2021, and assigned a price target of $106. Credit Suisse initiated its ‘Outperform’ rating for ALXO, as published in its report on May 05, 2021. Credit Suisse’s report from April 26, 2021 suggests a price prediction of $98 for ALXO shares, giving the stock a ‘Outperform’ rating. UBS also rated the stock as ‘Buy’.
Analysis of Alx Oncology Holdings Inc (ALXO)
In order to gain a clear picture of Alx Oncology Holdings Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -70.97% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.24, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 368.64K can be a very valuable indicator of volatility for ALXO stock. On a monthly basis, the volatility of the stock is set at 7.95%, whereas on a weekly basis, it is put at 6.87%, with a loss of -10.87% over the past seven days. Furthermore, long-term investors anticipate a median target price of $20.17, showing growth from the present price of $11.15, which can serve as yet another indication of whether ALXO is worth investing in or should be passed over.
How Do You Analyze Alx Oncology Holdings Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 45.78%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 57.89% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ALXO shares are owned by institutional investors to the tune of 57.89% at present.
